http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-175308-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_285f828afcbe0d96d2963238e7b793ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
filingDate 2014-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0233d21902c1a891da0a148e09224d4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63053d0317a15b075513f05aa40d5d2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44b29b03b85f4f10ce3e039722876e88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a474d1fedcdf5e142b987412140ea5a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3b4d4508bf8b7dbfbf482fe969db157
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1a9ba7ee1a142b24ce06a2b4418c750
publicationDate 2020-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MY-175308-A
titleOfInvention Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
abstract The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp, Rp stereoisomers thereof.
priorityDate 2013-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID72512
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID498840
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID340061
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID768990
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID533661
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410062813
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1044
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID101243556
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100127621

Total number of triples: 35.